Iptacopan (LNP023)
C3 Glomerulopathy (C3G)
Key Facts
About Novartis
Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.
View full company profileTherapeutic Areas
Other C3 Glomerulopathy (C3G) Drugs
| Drug | Company | Phase |
|---|---|---|
| OMS906 | Omeros | Phase 1b |
| Ruxoprubart (NM8074) | NovelMed Therapeutics | Preclinical/Phase 2 (not specified) |